Storys zum Thema Pharmaindustrie

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Norgine GmbH

Norgine Announces Appointment of New CEO Janneke van der Kamp

London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...

Grünenthal Group

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Fördergesellschaft IZB mbH

2

Record financing rounds at the Munich biotech hub

Bosch Healthcare Solutions GmbH

Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii

PAPACKS Sales GmbH

Bayer Collaborates with PAPACKS to Co-create Alternative-to-Plastic Packaging for Consumer Health Products

Technische Universität München

Multi-purpose mucus - What mucins can do in medicine

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE What mucins can do in medicine Multi-purpose mucus They are in our eyes, on our tongues, and in our stomachs: Protective layers of mucus, a slime consisting primarily of mucins. These are molecules which bind water to form a natural lubricant. Researchers at the Technical University of Munich (TUM) use them to develop coatings for contact lenses and intubation tubes, healing ...

RHEACELL GmbH und Co. KG

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Fraunhofer-Institut für Produktionstechnologie IPT

Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems

Aurubis AG

2

Press Release: Aurubis subsidiary RETORTE expanding selenium production for profitable growth markets

eleva GmbH

Björn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development

Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...

Adragos Pharma

Successful transaction: Adragos Pharma has officially taken over Clinigen’s development unit, Lamda Laboratories near Athens, Greece

Munich / London / Athens (ots) - - Adragos on a growth path: Three locations in Europe and five globally - Acquisition strengthens Adragos' end-to-end integrated pharmaceutical product development service offering - Agreement on further product development activities for Clinigen Munich-based pharmaceutical contract ...

Adragos Pharma

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories

Munich / London / Athens (ots) - - Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment - Agreement includes further product development activities for Clinigen Limited - Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich-based pharmaceutical contract ...

Adragos Pharma

Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan

Munich / Paris / Tokyo (ots) - - Adragos Pharma now third largest pure-play CDMO in the Japanese market - Long-term agreement with Sanofi secures local healthcare supply Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading ...

Fördergesellschaft IZB mbH

Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris

Technische Universität München

Nanoswitches for tumor targeting

TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...

RHEACELL GmbH und Co. KG

Stem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research

Adragos Pharma

Adragos Pharma to acquire Sanofi's manufacturing site in Kawagoe, Japan

benfovir AG

benfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)

Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...

LEUKOCARE AG

Leukocare announces new management structure to support global set-up and accelerate growth

Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board ...

benfovir AG

benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS

Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...

Technische Universität München

Multi-functional bandage helps wounds to heal

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808- email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37410 Pictures: https://mediatum.ub.tum.de/1659268 NEWS RELEASE Biomolecular film adheres to sensitive tissue and releases active ingredients Multi-functional bandage helps wounds to heal Researchers at the ...